SCHEMBL20914040

SCHEMBL20914040

CC(=O)NCCOc1cccc2oc(-c3c(C)[nH]c4c(-c5ccccc5)c(C(F)(F)F)nn4c3=O)nc12

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.35
▸ KDM4E B2RXH2 2/20 0.35
▸ HPGD P15428 1/20 0.35
▸ POLB P06746 2/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ MTNR1A P48039 5/20 0.33
▸ MTNR1B P49286 3/20 0.33
▸ SYK P43405 2/20 0.33
▸ CEPT1 Q9Y6K0 1/20 0.33
▸ DRD2 P14416 1/20 0.33
▸ DRD4 P21917 1/20 0.33
▸ DRD3 P35462 1/20 0.33
▸ MAT2A P31153 1/20 0.32
▸ F2RL3 Q96RI0 2/20 0.31
▸ LMNA P02545 1/20 0.31
▸ DGAT1 O75907 1/20 0.31
▸ ARF6 P62330 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20914304 0.89 DRD2 (0.33) ALDH1A1KDM4EPOLBMEN1KMT2A
SCHEMBL20914046 0.88 POLB (0.34) ALDH1A1KDM4EPOLBMEN1KMT2A
SCHEMBL20914003 0.88 ARF6 (0.34) ALDH1A1KDM4EPOLBMEN1KMT2A
SCHEMBL20914061 0.88 CEPT1 (0.37) ALDH1A1KDM4EPOLBMEN1KMT2A
SCHEMBL20914412 0.87 F2RL3 (0.37) ALDH1A1KDM4EPOLBMEN1KMT2A
SCHEMBL20913917 0.87 CEPT1 (0.36) ALDH1A1KDM4EPOLBMEN1KMT2A
SCHEMBL20914323 0.86 F2RL3 (0.41) ALDH1A1KDM4EPOLBMEN1KMT2A
SCHEMBL20819069 0.85 TNKS (0.37) ALDH1A1KDM4EHPGDPOLBMEN1
SCHEMBL20913904 0.84 POLB (0.34) ALDH1A1KDM4EPOLBMEN1KMT2A
SCHEMBL20913960 0.84 F2RL3 (0.41) ALDH1A1KDM4EPOLBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof NLRP3, NLRP1, P2RX7 ALDH1A1 1246/4885KDM4E 1922/4885HPGD 280/4885
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF NLRP3, NLRP1, P2RX7 ALDH1A1 1246/4885KDM4E 1922/4885HPGD 280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback